Gilead Sciences, Inc. (GILD)
|Net Income (ttm)||123.00M|
|Trading Day||March 3|
|Day's Range||62.17 - 63.32|
|52-Week Range||56.40 - 83.38|
Gilead to Present New Data at CROI 2021 Demonstrating the Company's Commitment to Addressing Urgent Global Health Needs
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new data from the company's HIV, hepatitis C virus (HCV), and COVID-19 r...
The battle against Covid-19 is about to get uglier. Coronavirus mutations threaten to undercut a year's worth of work upholding Covid stocks like Pfizer, Moderna and Regeneron Pharmaceuticals.
FATE reports a wider Q4 loss on increased R&D expenses.
Infinity Pharmaceuticals is my pick for Stock of the Year. And Shopify is my selection for Stock of the Decade.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: SVB Leerink Global Health...
Gilead (GILD) and partner Galapagos announce their decision to discontinue development of ziritaxestat in patients with idiopathic pulmonary fibrosis.
Kite Announces New ZUMA-1 Cohort Analysis Evaluating Prophylactic Corticosteroid Use With Yescarta® in Patients With Relapsed or Refractory Large B-cell lymphoma
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced findings from a new analysis of the ZUMA-1 trial of Yescarta® (axicabtagene ciloleucel) in adult p...
Despite solid signs of efficacy in mid-stage trials, the partners are shutting down all clinical trials with ziritaxestat.
Galapagos NV (NASDAQ: GLPG) and Gilead Sciences Inc (NASDAQ: GILD) have decided to stop the ISABELA Phase 3 studies evaluating ziritaxestat in patients with idiopathic pulmonary fibrosis (IPF)...
FOSTER CITY, Calif. & MECHELEN, Belgium--(BUSINESS WIRE)--Galapagos NV (Euronext & Nasdaq: GLPG) and Gilead Sciences (Nasdaq: GILD) today announced the decision to halt the ISABELA Phase 3 cli...
These biotechs are developing innovative therapies while doing their part to combat the coronavirus.
The unusual biotech could be a bitter pill for short sellers to swallow.
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced that Frank Neumann, MD, PhD, has joined the company as Senior Vice President and Global Head of Cl...
Gilead Sciences Inc (NASDAQ:GILD) earnings beat forecasts as sales of its antiviral drug remdesivir were boosted by its use as a treatment for coronavirus (COVID-19). Remdesivir is now treatin...
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry post their fourth-quarter earnings releases amid the coronavirus crisis.
Investors liked the big biotech's Q4 update.
Gilead (GILD) reports better-than-expected results for the fourth quarter owing to increased Veklury sales as the coronavirus pandemic continues.
Gilead Sciences Inc (NASDAQ: GILD) reported revenue in the fourth quarter of $7.3 billion, reflecting a 26% increase from the prior-year period revenue total of $5.8 billion, in-line with the ...
Without one drug, Gilead's Q4 update wouldn't have been a good one.
Gilead Sciences Inc. (NASDAQ: GILD) said on Thursday that its COVID-19 drug, Veklury, generated £1.39 billion of sales in the fiscal fourth quarter, making up 25% of the company's total quarte...
Gilead (GILD) delivered earnings and revenue surprises of 1.86% and 4.36%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Gilead Sciences (NASDAQ:GILD) rose after the company reported Q4 results. Quarterly Results Earnings per share were up 68.46% year over year to $2.19, which beat the estimate of $2.15.
Gilead Sciences Inc posted a 26% rise in quarterly revenue on Thursday, helped by sales of its antiviral drug, remdesivir, which is authorized to treat COVID-19 patients across the world.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company's Board of Directors has declared an increase of 4.4% in the company's quarterly cas...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2020. “Gilead continues to play a cent...
Gilead and the Human Rights Campaign Will Work Together to Combat HIV Epidemic and Promote Transgender Justice
FOSTER CITY, Calif. & WASHINGTON--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and the Human Rights Campaign (HRC), the nation's largest lesbian, gay, bisexual, transgender and queer ...
Covid-19 vaccines are getting all the glory after multi-bagger returns last year but these seven pharmaceutical stocks have a strong future ahead. The post 7 Pharmaceutical Stocks With Compell...
Gilead Sciences, Inc. (NASDAQ: GILD) said Monday that it has entered into a collaboration, option and license agreement with Gritstone Oncology Inc (NASDAQ: GRTS) to develop a vaccine-based im...
Arcus Biosciences Inc. disclosed Monday that Gilead Sciences Inc. boosted its stake in the oncology-focused biopharmaceutical company, through the purchase of $220.35 million worth of stock. A...
Gritstone Oncology shares soar 44% premarket on news of collaboration with Gilead to develop HIV therapy
Shares of Gritstone Oncology Inc. soared 44% in premarket trade Monday, after the company unveiled an agreement with Gilead Sciences Inc. to use Gritstone's vaccine platform technology to deve...
Gilead Sciences and Gritstone Announce Collaboration Utilizing Gritstone's Vaccine Platform Technology for HIV Cure
FOSTER CITY, Calif. & EMERYVILLE, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing n...
Earnings season is in full swing, and we have put together a preview of some of the world's largest players in the health care sector reporting this coming week.
Great dividends need to be sustainable, and that requires free cash flow.
Investors will focus on the HIV franchise's performance and Veklury sales when Gilead (GILD) reports fourth-quarter 2020 results.
In the latest trading session, Gilead Sciences (GILD) closed at $64.68, marking a -1.22% move from the previous day.
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Let us take a look at some drug/biotech stocks including Sanofi (SNY) and Merck (MRK) that are poised to beat fourth-quarter earnings estimates.
It's been a rocky past few months for the biotech, but is now a good time for investors to pull the trigger?
These are the recently approved treatments biotech investors want to keep their eyes on in 2021.
One has a top COVID-19 treatment, the other has a top COVID-19 vaccine. Which stock will come out on top.
Gilead Sciences (NASDAQ: GILD) shares are advancing this January, and at the current stock price, this company is fairly valued, in my opinion. The company is moving in the right direction, an...
Gilead has underperformed the S&P 500 in recent years, but that may be set to change as the company returns to growth with market valuations stretched. Gilead not only provides investors with ...
Gilead Sciences to Release Fourth Quarter and Full Year 2020 Financial Results on Thursday, February 4, 2021
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2020 financial results will be released on Thursday, February 4...
Gilead (GILD) gains more than 19% in the past month and is poised to post a robust performance in the year ahead on strong HIV franchise.
Both stocks provide payouts that put the average stock on the S&P 500 to shame.
A Wall Street analyst upgraded the biotech stock.
Gilead Sciences, Inc. (NASDAQ: GILD) and its R&D partner Galapagos ADR Representing Ord Shs (NASDAQ: GLPG) received an upgrade each from Morgan Stanley. The Gilead, Galapagos Analyst: Matthew ...
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced that Francesco Marincola, MD, will join the company as Senior Vice President and Global Head of Ce...
Merck and Amgen are major pharmaceuticals that experienced slowing sales in the mid 2010s due to patent expirations and biosimilar competition. However, Merck recently experienced strong botto...
Gilead Sciences (GILD) closed at $63.33 in the latest trading session, marking a +1.49% move from the prior day.
Gilead Sciences, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult... [Read more...]
|IPO Date |
Jan 22, 1992
|Stock Exchange |
|Ticker Symbol |
In 2020, GILD's revenue was $24.69 billion, an increase of 9.98% compared to the previous year's $22.45 billion. Earnings were $123.00 million, a decrease of -97.72%.
According to 32 analysts, the average rating for GILD stock is "Buy." The 12-month stock price forecast is 74.54, which is an increase of 18.79% from the latest price.